Drug intelligence / Profile preview

AD-923

Development stage: Phase 3
Modality: Small Molecules

Overview

AD-923 is an investigational drug formulation containing fentanyl, a potent opioid, along with excipients such as dehydrated alcohol, menthol, saccharin, and citrate buffer. It was investigated for the treatment of chronic breakthrough pain (CBP) in patients with malignancies. Fentanyl, the primary active ingredient, exerts its analgesic effects by acting as an agonist at mu-opioid receptors in the central nervous system.

Other names: fentanyl sublingual spray

Targets

DOR (Opioid Receptor Delta 1)MOR (Mu opioid receptor)KOR (Kappa opioid receptor)

Beyond the preview

Go deeper on AD-923.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AD-923.

Explore the full profile